- Cardiologists' Perspectives on Race-Based Drug Labels and Prescribing Within the Context of Treating Heart Failure. [Journal Article]Health Equity 2019; 3(1):246-253HE
- CONCLUSIONS: Few participants expressed approval of using race in drug prescribing without recognizing the potential harms, yet most participants stated that they continue to consider race when prescribing isosorbide dinitrate and hydralazine hydrochloride. Within the context of treating heart failure, more open discussions about the benefits and harms of race-based drug labels and prescribing are needed to address cardiologists' concerns.
- Expanded table: Some drugs for HFrEF. [Journal Article]Med Lett Drugs Ther 2019; 61(1569):e57-e62ML
- Drugs for chronic heart failure. [Journal Article]Med Lett Drugs Ther 2019; 61(1569):49-54ML
- Adherence to the evidence-based heart failure drug treatment: Are there sex-specific differences among new users? [Journal Article]Res Social Adm Pharm 2018; 14(10):915-920RS
- CONCLUSIONS: Among individuals initiating an evidence-based multi-drug treatment for HF, men are less likely than women to be adherent to this treatment.
- Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate in African-American Patients With Heart Failure. [Multicenter Study]JACC Heart Fail 2017; 5(9):632-639JH
- CONCLUSIONS: H-ISDN remains underused in African-American patients with HFrEF. In this cohort, the study found that H-ISDN use was associated with lower mortality rates in African-American patients with HFrEF when controlling for patient selection by using an inverse probability weighting of propensity scores.
- Fixed-Dose Versus Off-Label Combination of Isosorbide Dinitrate Plus Hydralazine Hydrochloride: Retrospective Propensity-Matched Analysis in Black Medicare Patients with Heart Failure. [Journal Article]Adv Ther 2017; 34(8):1976-1988AT
- CONCLUSIONS: The 1-year survival advantage for FDC-ISDN/HYD compared with off-label combinations in adherent black Medicare beneficiaries with HF suggests a genuine difference between these medications and warrants prospective investigation.
- An evidence-based review of recent advances in therapy for heart failure with reduced ejection fraction (HFrEF). [Review]Postgrad Med J 2016; 92(1094):726-734PM
- An estimated 5.1 million Americans have chronic heart failure and this is expected to increase 25% by 2030. Heart failure is a clinical syndrome that evolves from either functional or structural changes to the ventricles that lead to filling or ejection abnormalities. Thus far, pharmacotherapy has been show to be beneficial in patients only with reduced ejection fraction; however, new therapies h…
An estimated 5.1 million Americans have chronic heart failure and this is expected to increase 25% by 2030. Heart failure is a clinical syndrome that evolves from either functional or structural changes to the ventricles that lead to filling or ejection abnormalities. Thus far, pharmacotherapy has been show to be beneficial in patients only with reduced ejection fraction; however, new therapies have been developed in hopes of reducing the burden of heart failure. In this review, we will discuss current pharmacotherapies recommended in American College of Cardiology/American Heart Association guidelines, the evidence behind these recommendations as well as new and emerging therapies that have been developed.
- Dilemmas With Race and Heart Failure Treatment. [Journal Article]Circ Heart Fail 2016; 9(10)CH
- PGX: Pharmacogenomics During Generation X. [Editorial]Adv Chronic Kidney Dis 2016; 23(2):57-60AC
New Search Next
- Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate Therapy in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Get With The Guidelines-Heart Failure Registry. [Journal Article]Circ Heart Fail 2016; 9(2):e002444CH
- CONCLUSIONS: Guideline-recommended initiation of H-ISDN therapy at hospital discharge was uncommon, and adherence was low. For both black patients and patients of other races, there were no differences in outcomes between those treated and untreated at discharge.